Home > Cardiology > ISTH 2020 > Pearls of the Posters > Surgical bleeding risk most important determinant of bleeding outcomes

Surgical bleeding risk most important determinant of bleeding outcomes

Presented By
Dr Kira MacDougall, Staten Island University Hospital, USA
Conference
ISTH 2020
Trial
PAUSE
Results from the PAUSE study showed that neither type nor dose of direct oral anticoagulant (DOAC) influenced bleeding outcomes in AF patients undergoing elective surgery. The procedure itself carries the most evident bleeding risk for the patients [1]. The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study prospectively assessed a standardised perioperative management strategy in 3 cohorts of patients treated with a DOAC (i.e. apixaban, dabigatran, or rivaroxaban) who needed an elective surgery. The aim of the study, presented by Dr Kira MacDougall (Staten Island University Hospital, USA), was to compare rates of major bleeding, arterial thromboembolism, any bleeding (composite of major bleeding and clinically-relevant non-major bleeding), and any thromboembolism (composite of arterial and venous throm...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on